Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
M Sotelo, T Alonso-Gordoa, P Gajate… - Clinical and …, 2021 - Springer
Abstract Background The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the
efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer …
efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer …
[HTML][HTML] Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial …
Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …
Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
AIMS OF THE STUDY Atezolizumab is an approved therapy for urothelial carcinoma based
on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study …
on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study …
Clinical and economic outcomes in patients with metastatic urothelial carcinoma receiving first-line systemic treatment (the IMPACT UC I study)
MA Bilen, SB Robinson, A Schroeder, J Peng… - The …, 2023 - academic.oup.com
Abstract Background The IMPACT UC I study assessed real-world treatment patterns,
outcomes, healthcare resource utilization (HCRU), and costs in patients with metastatic …
outcomes, healthcare resource utilization (HCRU), and costs in patients with metastatic …
FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin‐containing …
DL Suzman, S Agrawal, Y Ning, VE Maher… - The …, 2019 - academic.oup.com
Abstract The US Food and Drug Administration (FDA) granted accelerated approval to
atezolizumab and pembrolizumab in April and May 2017, respectively, for the treatment of …
atezolizumab and pembrolizumab in April and May 2017, respectively, for the treatment of …
[PDF][PDF] Atezolizumab for locally advanced/metastatic urothelia l carcinoma within the compassionate use program in Spain: the IMcompass study
MA Duran, JL Perez-Gracia, JA Arrija - J Clin Oncol, 2022 - cuba.dialogoroche.com
ATEZOLIZUMAB FOR LOCALLY ADVANCED/METASTATIC UROTHELIAL CARCINOMA WITHIN
THE COMPASSIONATE USE PROGRAM IN SPAIN: THE IMCOMPASS S Page 1 …
THE COMPASSIONATE USE PROGRAM IN SPAIN: THE IMCOMPASS S Page 1 …
IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy …
MD Galsky, E Grande, ID Davis, M De Santis… - 2018 - ascopubs.org
TPS4589 Background: Platinum-based chemo is the standard of care for most pts with
untreated mUC, although clinical outcomes remain poor. Atezo (anti–PD-L1) was approved …
untreated mUC, although clinical outcomes remain poor. Atezo (anti–PD-L1) was approved …
Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Randomized Umbrella …
Purpose The MORPHEUS platform was designed to identify early efficacy signals and
evaluate the safety of novel immunotherapy combinations across cancer types. The phase …
evaluate the safety of novel immunotherapy combinations across cancer types. The phase …
A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC).
4559 Background: GC has a high overall response rate (ORR) but a high relapse rate in pts
with untreated mUC. Inhibition of programmed death-ligand 1 (PD-L1) with A can lead to …
with untreated mUC. Inhibition of programmed death-ligand 1 (PD-L1) with A can lead to …
Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract …
MD Galsky, R Banchereau, EE Kadel… - Annals of …, 2018 - annalsofoncology.org
Background: mUC arising from UTUC vs LTUC may involve distinct biology resulting in
different treatment responses & outcomes. However, this hypothesis has not been …
different treatment responses & outcomes. However, this hypothesis has not been …